Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells
AbstractVascular calcification is a frequent complication of atherosclerosis, diabetes and chronic kidney disease. In the latter group of patients, calcification is commonly seen in tunica media where smooth muscle cells (SMC) undergo osteoblastic transformation. Risk factors such as elevated phosphorus levels and vitamin D3 analogues have been identified. In the light of earlier observations by our group and others, we sought to inhibit SMC calcification via induction of ferritin. Human aortic SMC were cultured using β‐glycerophosphate with activated vitamin D3, or inorganic phosphate with calcium, and induction of alkaline phosphatase (ALP) and osteocalcin as well as accumulation of calcium were used to monitor osteoblastic transformation. In addition, to examine the role of vitamin D3 analogues, plasma samples from patients on haemodialysis who had received calcitriol or paricalcitol were tested for their tendency to induce calcification of SMC. Addition of exogenous ferritin mitigates the transformation of SMC into osteoblast‐like cells. Importantly, pharmacological induction of heavy chain ferritin by 3H‐1,2‐Dithiole‐3‐thione was able to inhibit the SMC transition into osteoblast‐like cells and calcification of extracellular matrix. Plasma samples collected from patients after the administration of activated vitamin D3 caused significantly increased ALP activity in SMC compared to the samples drawn prior to activated vitamin D3 and here, again induction of ferritin diminished the osteoblastic transformation. Our data suggests that pharmacological induction of ferritin prevents osteoblastic transformation of SMC. Hence, utilization of such agents that will cause enhanced ferritin synthesis may have important clinical applications in prevention of vascular calcification.
[…] Statistical analysis was performed with GraphPad Prism 5 and by one‐way anova test followed by post hoc Bonferroni's Multiple Comparison test. A significant value of P < 0.05 was marked with *, P < 0.01 with ** and P < 0.001 was marked with ***. Non‐significant (ns) differences were also marked. Data are shown as mean ± SD.Statistical analysis for Fig. C was performed employing Statistica for Windows. The variables were characterized by descriptive analyses (case number, median, quartiles). After comparing the results with Friedman anova, we used Wilcoxon matched pair test with Bonferroni correction to collate the paired samples. P ≤ 0.05 was considered significant. […]
to analyse the site's operation and effectiveness, to display ads tailored to your interests
and to provide you with relevant promotional messages and other information about products,
events and services of ours or our sponsors and partner companies.
These cookies are needed for the site to work and to be optimized.
These cookies are needed to interact with the social network plugins on this site.
These cookies are used to track visitors across websites.
The intention is to display ads that are relevant and engaging for the users.
These cookies are needed in order to better understand how
this site is used and to improve the user experience.
At omicX, we believe trust is of the utmost importance. Transparency allows trust.
This is why we want you to understand what data we collect and how we use it.